



CERTIFICATE OF ANALYSIS




Product Details

Product name:	Anti-CD20 & CD3 Reference Antibody (Odronextamab)	Lot.No.:	P247901
Target:	CD20, CD3	Catalog:	CHBA045
Target Accession:	P11836 & P07766	Concentration :	1 mg/mL
Clonality:	Bispecific	Isotype:	IgG-like
Reactivity:	Human	Molecular Weight (kDa) :	145.57 kDa
Application:	Kinetics (SPR), ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<1 EU/mg
Formulation:	Liquid: 100mM Pro-Ac, 20mM Arg pH 5.0 Lyophilization: 25mM histidine, 8% sucrose, 0.01% Tween80 pH6.2	Conjugation:	Unconjugated
Reconstitution:	For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.	Expression System:	CHO
Storage:	Upon receipt, store immediately at -20°C or lower for 24 months. Store aliquots at -80°C for up to 3 months. Avoid repeated freeze-thaw cycles.	Purification:	Protein A


Data

MASS




The detected molecular weight of Anti-CD20 & CD3 Reference Antibody (Odronextamab) is 145.34 kDa.

Purity: SDS-PAGE




Anti-CD20 & CD3 Reference Antibody (Odronextamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity: SEC-HPLC



The purity of Anti-CD20 & CD3 Reference Antibody (Odronextamab) is 97.48%, determined by SEC-HPLC.


ELISA



Odronextamab bound to CD20 protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP), and read OD450. As shown in fig, Odronextamab bound human CD20-VLP, and the EC50 was 0.1964 nM.


The products are for research use only. Not for use in diagnostic procedures.

Bioactivity: FACS




Odronextamab bound to Raji cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcy PE), and test by flow cytometry. As shown in fig, Odronextamab bound to Raji cells, and the EC50 was 17.3 nM.

Bioactivity: FACS



Odronextamab bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Odronextamab bound to huCD3e-jurkat cells, and the EC50 was 26.520 nM.

Function: Luciferase



Co-incubation of Odronextab with Jurkat cells, then with the addition of Raji cells for 6 hours. Bright-Lite was used to detect the fluorescent signal.

As shown in fig, Odronextamab was able to activate the NF-AT signaling pathway.

The products are for research use only. Not for use in diagnostic procedures.